The neuropathology/imaging core (Core D) is essential for the successful achievement of the aims of this program because all projects rely upon morphological methods. Since many of the core services are specialized, it would not be efficient or economical for individual project leaders to support the required equipment and expertise in their own laboratories. Core D will provide service, expertise, and equipment for the detection of huntingtin, apolipoprotein E and its fragments, alpha-synuclein, and amyloid beta peptides in cells and tissues, and for the morphological characterization of the neural alterations these molecules elicit. Specifically, Core D will provide advice on and assistance in specimen processing, embedding and microtomy of paraffin wax-embedded and frozen tissues, vibratome sectioning, histochemistry, immunohistochemistry, immunocytochemistry, in situ hybridization, quantitative morphometry of histological sections, quantitation of neuritic branching, stereological cell counting, digital photomicrography, image analysis, fluorescence confocal microscopy, video microscopy and routine and specialized electron microscopy of thin-sectioned neural tissue samples, and immunogold cytochemistry. Core D will train project personnel in morphological techniques, establish standardized protocols, and provide assistance in the interpretation of imaging and neuropathological data. Core D will also keep track of tissue samples and slides by means of an on-line database. The core will operate under the co-leadership of Dr. David Sanan, a specialist in microscopy, and Dr. Eliezer Masliah, an expert in neuropathology. All the equipment and laboratory facilities necessary for performing Core D operations are available at the Gladstone Institutes in San Francisco and Dr. Masliah's laboratory at the University of California at San Diego. The five projects will make extensive use of the core throughout the five-year period.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG022074-05
Application #
7431637
Study Section
Special Emphasis Panel (ZAG1)
Project Start
2007-06-01
Project End
2008-05-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
5
Fiscal Year
2007
Total Cost
$150,407
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Valera, Elvira; Spencer, Brian; Mott, Jennifer et al. (2017) MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy. Front Mol Neurosci 10:329
Valera, Elvira; Spencer, Brian; Fields, Jerel A et al. (2017) Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun 5:2
Overk, Cassia; Masliah, Eliezer (2017) Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. Alzheimers Dement 13:183-185
Spencer, Brian; Desplats, Paula A; Overk, Cassia R et al. (2016) Reducing Endogenous ?-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 36:7971-84
Spencer, Brian; Kim, Changyoun; Gonzalez, Tania et al. (2016) ?-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet 25:1100-15
Valera, Elvira; Masliah, Eliezer (2016) Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 139 Suppl 1:346-352
Spencer, Brian; Potkar, Rewati; Metcalf, Jeff et al. (2016) Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem 291:1905-20
Valera, E; Monzio Compagnoni, G; Masliah, E (2016) Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol 42:95-106
Valera, Elvira; Spencer, Brian; Masliah, Eliezer (2016) Immunotherapeutic Approaches Targeting Amyloid-?, ?-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 13:179-89
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34

Showing the most recent 10 out of 254 publications